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Biallelic loss-of-function (LOF) mutations of the NCF4 gene, encoding the p40phox subunit of the phagocyte NADPH oxidase,
have been described in only 1 patient. We report on 24 p40phox-deficient patients from 12 additional families in 8 countries.
These patients display 8 different in-frame or out-of-frame mutations of NCF4 that are homozygous in 11 of the families
and compound heterozygous in another. When overexpressed in NB4 neutrophil-like cells and EBV-transformed B cells
in vitro, the mutant alleles were found to be LOF, with the exception of the p.R58C and c.120_134del alleles, which were
hypomorphic. Particle-induced NADPH oxidase activity was severely impaired in the patients’ neutrophils, whereas PMAinduced dihydrorhodamine-1,2,3 (DHR) oxidation, which is widely used as a diagnostic test for chronic granulomatous disease
(CGD), was normal or mildly impaired in the patients. Moreover, the NADPH oxidase activity of EBV-transformed B cells was
also severely impaired, whereas that of mononuclear phagocytes was normal. Finally, the killing of Candida albicans and
Aspergillus fumigatus hyphae by neutrophils was conserved in these patients, unlike in patients with CGD. The patients suffer
from hyperinflammation and peripheral infections, but they do not have any of the invasive bacterial or fungal infections seen
in CGD. Inherited p40phox deficiency underlies a distinctive condition, resembling a mild, atypical form of CGD.
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Introduction

Chronic granulomatous disease (CGD) is a recessive primary
immunodeficiency (PID) caused by loss-of-function (LOF) mutations of autosomal or X-linked genes encoding 5 components of
the phagocyte-reduced NADPH oxidase complex (1). This enzyme
catalyzes the production of ROS in phagocytes. CGD was first
described in 1954 (2), the first functional disorder of phagocytes
was identified in 1966 (3), and the first genetic etiology of CGD,
which is X-linked recessive (XR), was discovered in 1986 in the
first positional identification of a PID gene (4, 5). The other genetic
etiologies proved to be autosomal recessive (AR) (6). Patients with
CGD suffer from recurrent, life-threatening, invasive infections
with specific bacteria and fungi (7–10). Severe parasitic infections
have rarely been reported in CGD patients, who also seem to have
no particular predisposition to severe viral illnesses (11). Systemic
hyperinflammation, including granulomatous lesions of the respiratory and gastrointestinal (GI) tracts in particular, is also common
(12–14). Patients with CGD may initially present with unexplained
granulomatosis, which is associated with a poor prognosis, (13,
15). Autoimmune conditions, such as systemic lupus erythematosus, are rare in patients with CGD (16). The XR (gp91phox [phagocyte oxidase]) form of CGD is clinically more severe than the AR
p47phox-deficient form (7, 9, 17). AR p22phox and p67phox deficiencies
appear to be as severe as XR CGD (18, 19). Patients are routinely
placed on prophylactic antimicrobial therapy, and the only curative treatment widely available is allogeneic hematopoietic stem
cell transplantation (HSCT) (20).
The NADPH oxidase in human phagocytes is a complex of at
least 5 subunits. The membrane-bound component is a hetero
dimer consisting of gp91phox and p22phox, encoded by the X-linked
CYBB gene and the autosomal CYBA gene, respectively. This
heterodimer is known as flavocytochrome b558 and is the catalytic
core of the NADPH oxidase complex (21). The second component is a cytosolic heterotrimer composed of p40phox, p47phox, and
p67phox, which form the regulatory part of the NADPH oxidase and
are encoded by NCF4, NCF1, and NCF2, respectively (22). The
membrane-bound and cytosolic components do not interact in
steady-state conditions. Upon phagocyte activation, after the
phagocytosis of a bacterium or fungus, for example, the 2 components and a small GTPase (Rac1 and/or Rac2) are activated and
assemble on the phagosomal membrane to produce superoxide
(O2–) in the phagosome (23). This O2– is subsequently converted
into hydrogen peroxide (H2O2) and other ROS, which together
contribute to the destruction of the phagocytized microorganisms.
LOF mutations of CYBB underlie the XR form of CGD, whereas
LOF mutations of CYBA, NCF1, and NCF2 underlie the AR forms.
Hypomorphic mutations of some of these genes have been shown
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to underlie variant CGD, in which residual activity does not differ between cell types (24). Hypomorphic CYBB mutations, which
are more deleterious in monocyte-derived macrophages (MDMs)
than in peripheral phagocytes, have been shown to underlie Mendelian susceptibility to mycobacterial disease (MSMD) (25).
Much less is known about the fifth component, p40phox, as
biallelic mutations of NCF4 have only been described once before
in a young boy with severe colitis (26). p40phox has 3 domains: PX,
PB1, and SH3 (27, 28). During phagocytosis, upregulation of the
membrane phospholipid phosphatidylinositol 3-phosphate [PI(3)
P] and subsequent high-affinity binding of the p40phox PX domain
enhance NADPH oxidase activity (21, 29). The p40phox-deficient
patient is compound heterozygous for a premature stop codon
and a missense mutation in the PX domain that compromises
binding to PI(3)P, which results in the impairment of neutrophil
phagocytosis–induced oxidase activity (26). As in classic CGD
neutrophils, intracellular oxidant production after stimulation
with serum-opsonized zymosan (SOZ), IgG beads, or serumopsonized Staphylococcus aureus is impaired in the patient’s neutrophils, and S. aureus killing is also defective (20, 26, 30). However, in this patient, unlike in classic CGD patients, the production of O2– by neutrophils in response to stimulation with PMA
or formyl-methionyl-leucyl-phenylalanine (fMLF) is normal
(26). The killing of S. aureus by neutrophils is also impaired in
p40phox–deficient and CGD mice (31). However, p40phox-deficient
murine neutrophils display highly impaired ROS production upon
stimulation with PMA or heat-killed S. aureus, but not SOZ (32).
Moreover, gp91phox- and p47phox-KO mice (33–35) seem to have a
less severe form of inflammatory colitis than do p40phox-KO mice
(36, 37). The cellular and clinical overlap and differences between
human p40phox deficiency and classic CGD are largely unknown.
Here, we describe the characteristics of 24 patients from 12 families in 8 countries with biallelic mutations of NCF4.

Results

Biallelic NCF4 mutations in 24 individuals from 12 families in 8 countries. We studied 20 patients from 12 families with clinical features
suggestive of CGD (kindreds A–L) (Tables 1 and 2 and Figure 1A).
The families originated from Pakistan (kindreds A, B, E, and F),
Portugal (kindreds C and J), Australia (kindred D), Colombia
(kindred G), Argentina (kindred H), Kuwait (kindred I), Russia
(kindred K), and Chile (kindred L). Whole-exome sequencing
(WES) or targeted next-generation sequencing (NGS) with a panel
of PID genes identified homozygous variants of the NCF4 gene
in patients from 11 families: 2 variants affecting essential splice
sites (c.118-1G>A in kindreds A, E, and K and c.32+2T>G in kindred F); 3 missense variants (c.314G>A in kindred B, resulting in
p.R105Q; c.172C>T in kindreds G and L, resulting in p.R58C; and
c.430C>A in kindred H, resulting in p.P144T); 1 nonsense variant
(c.716G>A in kindred I, resulting in p.W239X); and 1 in-frame
deletion (c.120_134del in kindreds C and J). Finally, we detected
compound heterozygous splice-site variants in 1 family (c.1181G>A and c.759-1G>C in kindred D). All variants were verified by
Sanger sequencing. In 11 kindreds, the familial segregation of the
alleles was consistent with an AR trait. Kindred J displayed uniparental isodisomy (UPD), as both copies of chromosome 22 were
inherited from the father (Figure 1A and ref. 38). Four asymptom-
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Figure 1. Identification of NCF4
mutations. (A) Pedigrees of 12 families
showing allele segregation. The index
cases are indicated by an arrow, and
“E?” indicates an unknown genotype.
Black or white symbols represent
individuals with or without clinical
manifestations, respectively. Triangles
represent pregnancies not carried
to term. m, mutated. (B) Schematic
diagram of the structure of the NCF4
gene and p40phox protein, consisting
of 9 exons and 3 protein domains,
respectively. Newly discovered and
previously reported mutations of the
NCF4 gene are noted according to their
localization. Red asterisks indicate
mutations previously reported by
Matute et al. (26).
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c.32+2T>G/ 32+2T>G

P13 (II.4)
P14 (II.5)

F

Yes

Yes

No

No

Pakistan (living
in UK)

Pakistan (living
in UK)

USA

Portugal

M
F

F

M

F

M

Alive
Alive

Alive

Alive

Alive

Alive

Alive

Alive

Alive

Alive

Alive

Alive

Alive

Alive

–
2

1

7

1

5

4

3

7

Unknown

5

Unknown

9

4

Age at onset of symptoms (yr)

1
5

2

10

1

7

9

15

16

19

23

46

14

9

Age at CGD
diagnosis (yr)

Asymptomatic. Prophylaxis: cotrimoxazole and itraconazole.
Recurrent respiratory infections (BAL: viruses and Candida),
bronchiectasis. Bilateral dense consolidation on lung CT. Chronic
interstitial inflammation on lung biopsy, successfully treated with
an i.v. pulse of methylprednisolone. Lymphadenitis with abscesses.
Positive for C-ANCA and ANA. Prophylaxis: cotrimoxazole/
itraconazole. In work-up for HSCT.

Mouth ulcers, IBD with colonic granulomata, poorly responsive
to mesalazine; S. aureus skin abscesses. ANA-negative. BCG
vaccination with no AE. Prophylaxis: cotrimoxazole/itraconazole.
Lupus-like skin lesions, no IBD symptoms. ANA-negative.
Prophylaxis: cotrimoxazole/itraconazole.
Lupus-like skin lesions in childhood. ANA/anti-dsDNA Ab–negative.
Prophylaxis: none.
Recurrent MRSA skin infections, eczema. ANA-negative.
Prophylaxis: none.
Non-necrotizing granulomatous inflammation of the gums and
skin. AFB/fungus-negative. ANA-negative. Prophylaxis: none.
Recurrent skin infections; lupus-like skin lesions; seborrheic
dermatitis. Prophylaxis: cotrimoxazole/itraconazole.
Impetigo; discoid lupus. SM, GPC, mitochondrial defects, reticulin,
LKM-negative. Prophylaxis: cotrimoxazole/itraconazole/
hydroxychloroquine.
Skin abscesses (MRSA/GBS), impetigo; lupus-like skin lesions.
ANA, ANCA, TPO, C1q Abs: negative. Prophylaxis: cotrimoxazole/
itraconazole/hydroxychloroquine.
Dental and cutaneous abscesses; periodontitis. BCG vaccination
with no AE. Prophylaxis: cotrimoxazole/itraconazole.
Recurrent oral ulcers, no IBD symptoms. BCG vaccination with no
AE. Prophylaxis: cotrimaxozole/itraconazole.
Cutaneous discoid lupus erythematosus complicated by S. aureus
skin infection; anal fissures, mouth ulcers, cryptitis in descending
colon, sigmoid and rectum. Prophylaxis: none; after HSCT.
Chronic fever, recurrent pulmonary infections (no positive
cultures). Lung, lymph node. Granulomata. ANA, ANCA, ENAs
dsDNA Abs: negative. Cardiolipin G 87.6 GPLU (0–5.7). Prophylaxis:
cotrimoxazole and itraconazole.

Clinical phenotype (infections, autoimmunity, microbiology,
imaging, pathology results) Prophylaxis/current treatment;
HSCT

AE, adverse effect; AFB, acid-fast bacilli; BAL, bronchoalveolar lavage; dsDNA, double-stranded (ds, native) DNA; LKM, anti–liver-kidney microsomal Ab; GPC, gastric cell parietal Ab; MRSA/GBS, methicillinresistant Staphylococcus aureus/group B Streptococcus; SM, anti-Smith; TPO, thyroperoxidase Abs.

c.118-1G>A/ 118-1G>A

P12 (II.3)

E

c.118-1G>A/c.759-1G>C

P11 (II.1)

P10 (II.2)

c.120_134del/120_134del

F

P8 (IV.9)

P9 (II.1)

F

P7 (IV.6)

D

C

M

P6 (IV.5)

F

M

Pakistan (living
in UK)

M

P5 (IV.4)

Yes

Pakistan (living
in UK)

Sex (F/M) Follow-up

M

p.R105Q/R105Q

Yes

Origin

P4 (IV.1)

P2 (IV.7)

B

c.1181G>A/, 118-1G>A

Consanguinity

M

P1 (II.1)

A

Mutation

P3 (III.1)

Patient

Kindred

Table 1. The clinical spectrum of p40phox deficiency
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P20 (II.1)

H

I

P23 (II.4)

P24 (II.3)

K

L

p.R58C/R58C

c.118-1G>A/ 118-1G>A

c.120_134 del/120-134del

No

No

No

Yes

No

No

Consanguinity

Chile

Russia (born in
Germany)

Portugal

Kuwait (living in
Belgium)

Argentina

Columbia

Origin

F

F

F

F

F

M
F
M
F

M

Alive

Alive

Alive

Alive

Alive

Alive
Alive
Alive
Alive

Alive

Sex (F/M) Follow-up

17

11

2

8

14

–
–
–
1

2

Age at onset of symptoms (yr)

6MP, 6-mercaptopurine; ASCAs, anti–Saccharomyces cerevisiae Abs; LNs, lymph nodes; MTX, methotrexate.

P22 (II.2)

J

P21 (II.3)

p.P144T/ P144T

P16 (II.3)
P17 (II.4)
P18 (II.8)
P19 (II.1)

p.W239X/ W239X

p.R58C/R58C

P15 (II.5)

G

Mutation

Patient

Kindred

Table 2. The clinical spectrum of p40phox deficiency

23

17

15

32

37

10
8
3
7

6

Age at CGD
diagnosis (yr)

Chronic fever. Chronic diarrhea. Oral thrush (no microbiology
results). Recurrent disseminated histoplasmosis (LNs, liver,
spleen, serum, urine, BM), successfully treated with amphotericin
B, itraconazole and fluconazole. BCG-vaccine: no AE. Prophylaxis:
cotrimoxazole/itraconazole.
Asymptomatic. BCG vaccine with no AE. Prophylaxis: none.
Asymptomatic. BCG vaccine with no AE. Prophylaxis: none.
Asymptomatic. BCG vaccine with no AE. Prophylaxis: none.
Pneumonia. Regional lymphadenitis (BCG-itis). Cutaneous lesions
(granulomatous, no organisms detected, stains/PCR not available).
Meningitis due to M. avium complex. Prophylaxis: none.
Gastritis, severe complex perianal fistula with recurrent abscesses
and anal stenosis. Adenocarcinoma of anal canal. Treatment:
steroids, azathioprine, infliximab, golimumab. Chemo- and
radiotherapy for adenocarcinoma. Prophylaxis: none, after HSCT.
Esophageal ulcerations and severe perianal fistula diagnosed as
Crohn’s disease. Recurrent skin abscesses. Episcleritis. Severe
periodontitis. Treatment: steroids, adalimumab, high-dose proton
pump inhibitors. Prophylaxis: none, after HSCT.
IBD with granuloma in colon. Vulvar lichen planus (at 2 yr of
age). Pilonidal cyst surgery. ASCA-positive. BCG vaccine with no
AE. Treatment: steroids, infliximab, adalimumab, thalidomide.
Prophylaxis: cotrimoxazole.
IBD with granulomata in oral mucosa, esophagus and colon.
Recurrent blepharitis/conjunctivitis. Treatment: steroids, MTX,
ustekinumab; exclusive enteral nutrition, mesalazine, azathioprine,
tacrolimus, colchicine, IFN-γ, adalimumab and/or anakinra were
ineffective. Prophylaxis: cotrimoxazole.
IBD with colonic granulomata and severe perianal disease.
Erythema nodosum and pyoderma gangrenosum. Treatment:
ciprofloxacin, mesalamine, and prednisolone. Chronic, refractory
disease despite escalating immunomodulatory (azathioprine,
6MP) and biological (adalimumab, infliximab, natalizumab) drugs.
Total colectomy with ileostomy; return of symptoms after surgery.
Infliximab. Prophylaxis: none.

Clinical phenotype (infections, autoimmunity, microbiology,
imaging, pathology results) Prophylaxis/current treatment;
HSCT
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Figure 2. p40phox levels and
NADPH oxidase activity of
the NCF4-mutated alleles. (A)
Western blot of total protein
extracts from HEK293T cells
expressing NCF4 cDNAs. The
upper-panel data were obtained
with a polyclonal anti-p40phox
Ab, and the lower-panel data
were obtained with an anti–DDK
(Flag) Ab. An Ab against GAPDH
was used as a loading control.
(B) Western blot of total protein
extracts from healthy control and
NCF4–/– EBV–B cells retrovirally
transduced with NCF4 cDNAs. A
polyclonal anti-p40phox Ab was
used, with an Ab against GAPDH
as the loading control. NT, not
transduced. (C) Production of O2–
by NCF4–/– EBV–B cells retrovirally
transduced with NCF4 cDNAs
upon PMA stimulation. The
results are representative of 2
independent assays. LU, luminescence units. (D) DHR reaction of
NB4 p40phox-KO cells stimulated
with PMA or (E) with E. coli. (F)
Killing activity of NB4 p40phox-KO
cells infected with S. aureus (n =
2–3). Data represent the mean ±
SEM (n ≥3) or the mean only (n
<3) and were analyzed using a
2-tailed Mann-Whitney U test.
EV, empty vector.
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atic individuals were shown to carry biallelic mutations (kindreds
E and G) (Figure 1A). None of the variants, other than p.R58C
(minor allele frequency [MAF] = 0.001), was found in public databases (Exome Aggregation Consortium [ExAC], Human Gene
Mutation Database [HGMD], gnomAD, and Biomarker Recognition and Validation Online [BRAVO]) or in our in-house WES
database (~4,500 WES). Furthermore, combined annotationdependent depletion (CADD) scores predicted all mutations to be
deleterious, as these scores were above or close to the mutation
significance cutoff (MSC) (ref. 24 and Supplemental Figure 1A;
supplemental material available online with this article; https://
doi.org/10.1172/JCI97116DS1). The 3 missense mutations affect
residues located in the PX domain of the p40phox protein (Figure
1B). These residues are highly conserved in other species, suggesting that they have an important function in the p40phox protein (Supplemental Figure 1B). We searched for a founder effect
accounting for the presence of the c.120_134del, c.118-1G>A, and
p.R58C mutations in different families. The patients homozygous
for these mutations were genotyped with the genome-wide array
6.0. The c.120_134del mutation in 2 Portuguese families (kindreds
C and J) is within a common haplotype of 884 kb and 1,926 SNPs,
demonstrating a founder effect. We dated the most recent common ancestor (MRCA) to 175 years ago (CI: 50–650 years). The
c.118-1G>A variant in patients from Pakistan (kindreds A and E) is
within a common haplotype of 337 kb and 136 SNPs. The MRCA
of these kindreds was dated to 1,950 years ago (CI: 625–8,075
years). The patient from Russia (kindred K) also shared a common
haplotype of 152 kb and 41 SNPs in common with the 2 Pakistani
patients, suggesting a common ancestor for these 3 patients, and
the MRCA was estimated to have lived 6,275 years ago (CI: 2,475–
19,000 years) (39). Finally, the c.172C>T (p.R58C) mutation, present in 2 Latin American kindreds, was within a common haplotype
of 122 kb and 47 SNPs. The MRCA of these kindreds was dated to
4,425 years ago (CI: 1,375–16,025 years). Collectively, these data
suggest that 24 individuals from 12 kindreds in 8 countries suffer
from inherited p40phox deficiency, including 20 symptomatic and 4
asymptomatic individuals (Figure 1A).
Impaired NCF4 mRNA expression in the patients’ cells. We
measured NCF4 transcript levels in cells from the patients and
healthy controls by quantitative real-time RT-PCR (qPCR). EBVtransformed B cell lines (EBV–B cells) and neutrophils homozygous for c.32+2T>G (patient 14 [P14]) produced no NCF4 transcripts detectable by qPCR (Supplemental Figure 2A) or cDNA
PCR (data not shown). These findings suggest that transcripts carrying this mutation are subjected to nonsense-mediated mRNA
decay. For P12 (c.118-1G>A), P15 (p.R58C), P20 (p.W239X), and
P22 (c.120_134del), we found that NCF4 transcript levels in EBV–B
cells and neutrophils were lower than those in 10 unrelated controls (Supplemental Figure 2A). Cells homozygous for c.118-1G>A
or c.120_134del produced transcripts of lower molecular weight
(MW), suggesting the occurrence of alternative splicing. Using
TOPO-TA cloning, we detected 3 aberrantly spliced variants for
c.118-1G>A, all of which were predicted to encode truncated proteins, and we identified a fourth minor transcript (6%) with a large
in-frame deletion, c.118_198del (Supplemental Figure 2B). For
c.120_134del, most of the transcripts carried a 5-codon deletion
(p.F41_V45del) at the beginning of exon 3, and another 3 aberrant-
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ly spliced variants were predicted to encode truncated proteins
(Supplemental Figure 2B). Finally, for the c.759-1G>C allele, we
performed exon trapping. We obtained 3 spliced variants: 1 with
the retention of 37 bp of intron 8a (63%), 1 in which all of intron 8a
was retained (26%), and 1 with the retention of 16 bp of intron 8a
(11%) (Supplemental Figure 2C).
The mutant NCF4 alleles are deleterious in EBV–B cells. We
assessed the potential impact of all individual NCF4 alleles. We
used HEK293T cells for analyses of p40phox protein expression,
whereas, for analyses of p40phox function, we used EBV–B cells from
P14 (homozygous for c.32+2T>G), designated NCF4 –/–, as they
produced no detectable NCF4 mRNA. We first evaluated protein
expression by transfecting HEK293T cells with expression vectors
carrying C terminally Flag-tagged WT or mutant NCF4 cDNAs
(R58C, R105Q, P144T, W239X, c.118_198del, and c.120_134del).
Immunoblot analyses revealed that the WT, R58C, R105Q, and
P144T cDNAs encoded a single, full-length 40-kDa protein that
was produced in large amounts. By contrast, cells transfected with
the in-frame deletions c.118_198del and c.120_134del produced
proteins with a lower MW, at much lower abundance. Finally, the
protein encoded by W239X cDNA was not detected with an antiFlag Ab, whereas a truncated protein of approximately 25 kDa
gave a low-intensity signal with an anti-p40phox Ab (Figure 2A). We
investigated the mode of functioning of the mutant alleles (LOF
or hypomorphic) in EBV–B cells, which express all components of
the NADPH oxidase complex and produce ROS (25, 26, 40). We
transduced NCF4 –/– EBV–B cells from P14 with retroviruses for the
overexpression of missense (R58C, R105Q, and P144T), in-frame
deletion (c.120_134del), and nonsense (W239X) cDNAs. Western
blotting confirmed that the missense proteins were expressed normally, whereas c.120_134del was produced in small amounts, and
the W239X protein was undetectable (Figure 2B). We then evaluated ROS production in NCF4 –/– EBV–B cells by measuring O2–
levels after PMA stimulation. EBV–B cells transduced with the
R58C, R105Q, P144T, c.118_198del, p.Asp254Serfs96*, and
W239X alleles produced no detectable O2–. By contrast, retrotransduction with the c.120_134del variant led to a small, reproducible
increase in O2– production (Figure 2C). No H2O2 was generated
following the retrovirus-mediated transduction of NCF4 –/– EBV–B
cells with any of the mutant alleles in these conditions (Supplemental Figure 3A). These data suggest that 6 of the 7 alleles tested
were LOF, with the remaining allele (c.120_134del) being severely
hypomorphic, at least under these experimental conditions.
The mutant NCF4 alleles are deleterious in NB4 cells. We then
generated CRISPR-Cas9–KO p40phox NB4 cells, which we allowed
to differentiate into neutrophil-like cells. NADPH oxidase activity
and S. aureus killing capacity were assessed in p40phox WT cells,
NB4-p40phox–KO cells, and in NB4-p40phox–KO cells reconstituted
with alleles R105Q, R58C, c.120_134del, or c.118_198del or WT
p40phox. We observed no decrease in PMA-induced extracellular
H2O2 release or intracellular H2O2 generation in NB4-p40phox–
KO cells, as was the case with cells reconstituted with any of the
mutant alleles, consistent with the results obtained with neutrophils from the previously reported p40phox-deficient patient (Figure 2D, Supplemental Figure 3B, and ref. 26). Assessments of
extracellular H2O2 release in response to serum-opsonized E. coli
and A. fumigatus hyphae showed that NADPH oxidase activity was
jci.org   Volume 128   Number 9   September 2018
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Figure 3. p40phox and NADPH oxidase subunit expression in p40phox-deficient cells. (A) Western blot of total protein extracts from the neutrophils of healthy
controls, patients, and heterozygous relatives. Abs against p40phox protein were used. Actin or GAPDH protein was used as a loading control. (B) Western
blot of total protein extracts from MDMs and MDDCs from a healthy control and p40phox-deficient patients. Detection was done with a polyclonal anti-p40phox
Ab, and an Ab against GAPDH was used as a loading control. (C) Western blot of total extracts from EBV–B cells from a healthy control, p40phox-deficient
patients, and XR and AR CGD patients. Abs against p40phox protein or gp91phox, p22phox, p67phox, and p47phox were used. Actin or GAPDH protein was used as a
loading control. (D) Intracellular detection of gp91phox, p22phox, p67phox, and p47phox in EBV–B cells from a healthy control, p40phox-deficient patients, and XR and
AR CGD patients. The results shown are representative of 2 independent assays. p40phox–/– indicates a patient reported in a previous study (26).
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impaired in NB4-p40phox–KO cells (Supplemental Figure 3B). This
defect was restored by reconstitution with WT p40phox or the R58C
allele, but not with the other 3 mutant alleles (Supplemental Figure
3B). Nevertheless, for E. coli–induced intracellular DHR oxidation,
only WT p40phox restored the NADPH oxidase activity (Figure 2E).
Moreover, S. aureus killing was impaired in NB4-p40phox–KO cells
as well as in cells reconstituted with the mutant alleles, except for
the R58C allele (Figure 2F). These experiments suggest that the
R105Q, c.120_134del, and c.118_198del alleles are LOF in terms of
ROS production and S. aureus killing in NB4 cells. In contrast, the
R58C allele is hypomorphic in the same experimental conditions.
Collectively, these data indicate that all the NCF4 alleles tested
are LOF, with the exception of c.120_134del in EBV–B cells and
R58C in NB4 cells, at least upon overexpression.
Impaired p40phox expression in the patients’ phagocytes. We
studied the expression of endogenous p40phox by Western blotting in neutrophils, monocytes, MDMs, and monocyte-derived
dendritic cells (MDDCs). We detected no p40phox protein in neutrophils from P1 (c.118-1G>A), P9 or P10 (c.120_134del), P11
(c.118-1G>A/c.759-1G>C), P12 (c.118-1G>A), P14 (c.32+2T>G),
P22 (c.120_134del), or P23 (c.118-1G>A). By contrast, neutrophils from P6 and P8 (R105Q) and from P15 and P16 (R58C) had
normal levels of p40phox protein. Neutrophils from P20 (W239X)
contained a lower-MW protein present at low abundance (Figure
3A), which was consistent with the truncated protein observed
upon W239X overexpression in HEK293T cells (Figure 2A).
Western blotting also revealed that the levels of the other components of the NADPH oxidase complex in the patients’ neutrophils were normal (Supplemental Figure 4). Finally, we detected
no p40phox protein in MDMs or MDDCs from P12, P20, or P22,
(Figure 3B). Thus, these mutations result in a loss of p40phox
expression in various types of myeloid cells. Collectively, these
data are consistent with those obtained for the overexpression of
mutant cDNAs in recipient cells.
Impaired p40phox expression in the patients’ EBV–B cells. We performed Western blotting to study the expression of the NADPH
oxidase subunits in EBV–B cells (26). We observed a complete
loss of expression of the p40phox protein in EBV–B cells from P12,
P14, P20, and P22. By contrast, p40phox was detected, but at low
abundance, in cells from P15 (Figure 3C). The other subunits of
the NADPH oxidase complex, gp91phox, p22phox, and p47phox, were
normally expressed in the cells of all patients, as shown by Western blotting and flow cytometry with intracellular staining (Figure
3, C and D) and by comparing with expression levels in gp91phox-,
p22phox-, and p47phox-deficient patients. However, the expression
of p67phox, which interacts with p40phox, was affected in the EBV–B
cells (Figure 3D), but not the neutrophils (Supplemental Figure
4). These findings indicate that p40phox is involved in stabilizing
p67phox levels in EBV–B cells, but not in neutrophils.
Residual to normal levels of NADPH oxidase activity in
p40phox-deficient neutrophils exposed to soluble inducers. We studied the impact of NCF4 mutations on NAPDH oxidase activity by evaluating ROS production in patients’ cells. The PMAinduced DHR test, which measures intracellular H2O2 generation, is
widely used on neutrophils for the diagnosis of classic CGD (1).
This test showed a wide range of intracellular ROS production
activity in p40phox-deficient neutrophils, from completely normal
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oxidase activity to residual levels of activity, but always markedly
higher than those in classic CGD cells (Figure 4A). We observed
a similar pattern at several time points (Supplemental Figure 5A).
The release of H2O2 and production of O2– were evaluated after
stimulation with PMA, platelet-activating factor (PAF) plus fMLF,
or SOZ. We found that H2O2 generation by the patients’ neutrophils was normal or subnormal, whereas neutrophils from patients
with classic CGD produced no H2O2 or O2– (Supplemental Figure
4C). Thus, neutrophils from p40phox-deficient patients had normal or impaired, but not abolished, ROS production as shown by
extracellular detection tests, contrasting sharply with the results
for neutrophils from patients with classic CGD.
Impaired NADPH oxidase activity in p40phox-deficient neutrophils exposed to particulate inducers. As previously reported in
p40phox-KO mice, ROS production in neutrophils in response to
particulate stimuli depends on the recruitment of p40phox protein
to the endosomes (31). We therefore evaluated intracellular and
extracellular ROS production by the patients’ neutrophils following stimulation with serum-opsonized S. aureus, E. coli, A. fumigatus hyphae, or C. albicans. Particle-induced intracellular DHR
oxidation after neutrophil stimulation with S. aureus or E. coli was
severely impaired in all patients tested, as in neutrophils from
patients with classic CGD (Figure 4B). By contrast, DHR oxidation
in neutrophils stimulated with unopsonized or serum-opsonized
C. albicans conidia was only partially impaired in the p40phoxdeficient patients, whereas a more pronounced defect was
observed in the neutrophils from patients with classic CGD (Figure 4C). Moreover, extracellular H2O2 release by the neutrophils
of p40phox-deficient patients in response to S. aureus, E. coli, or
A. fumigatus was only partially impaired (Supplemental Figure
5D). Finally, oxygen consumption was slightly impaired in the
cells of all p40phox-deficient patients tested after stimulation with
either soluble (PMA) or particulate (E. coli, SOZ) stimuli (Supplemental Figure 5E). We found that neutrophils lacking gp91phox
had no activity at all. Heterozygous carriers of p40phox deficiency
displayed no defects of ROS production (data not shown). These
findings confirm that p40phox plays an essential role in the NADPH
oxidase activity of neutrophils upon stimulation with bacteria and,
to a lesser extent, fungi, suggesting the translocation of at p40phox
to assist in activation of the NADPH oxidase complex in response
to these microorganisms.
Normal NADPH oxidase activity in other myeloid cells from the
patients. We demonstrated that p40phox expression in some patients
was equally impaired in different types of phagocytes (Figure 3).
We analyzed the effects on NADPH oxidase activity in these cells
by evaluating ROS production in monocytes triggered by PMAinduced DHR oxidation. Monocytes from 6 patients (P12, P15,
P16, P19, P20, and P22) responded similarly to cells from healthy
controls (Supplemental Figure 5B). We further investigated
the NADPH oxidase activity of MDMs, as previously described
(25, 41). MDMs from healthy controls, P12, P20, and P22 had normal or low levels of H2O2 after stimulation, depending on the stimulus, whereas MDMs from a patient with classic CGD released no
H2O2 (Figure 5A). Finally, we assessed NADPH oxidase activity in
MDDCs, again evaluating H2O2 release. We found that MDDCs
from the 3 patients tested (P12, P20, and P22) released normal
amounts of H2O2, as shown by comparison with MDDCs from
jci.org   Volume 128   Number 9   September 2018
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Figure 4. NADPH oxidase activity in p40phoxdeficient neutrophils. (A) Intracellular ROS production by DHR in neutrophils from healthy controls
(n = 37), p40phox-deficient patients (n = 17), and
CGD patients (n = 5) upon PMA stimulation (100 ng
PMA/ml and 400 ng/μl). (B) Particle-induced DHR
oxidation in neutrophils from healthy controls
(n = 17 and n = 23), p40phox-deficient patients (n = 12
and n = 14), and CGD patients (n = 3 and n = 6) upon
stimulation with S. aureus (left) or E. coli (right). (C)
DHR oxidation in neutrophils from healthy controls
(n = 14 and n = 6), p40phox-deficient patients (n = 6
and n = 5), and CGD patients (n = 4 and n = 3) upon
addition of C. albicans, with (left) or without (right)
opsonization. PMNs, polymorphonuclear neutrophils. Data represent the mean ± SEM.
*P < 0.05, **P < 0.01, and ***P < 0.001, by 2-tailed
Mann-Whitney U test.
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healthy controls, and unlike MDDCs from classic CGD patients
(Figure 5B). Overall, these data suggest that p40phox is redundant in
monocytes, MDMs, and MDDCs in terms of the NAPDH oxidase
activity triggered by PMA. Further experiments assessing particleinduced ROS production by monocytes, MDMs, and MDDCs are
required to determine the extent of this redundancy.
Impaired NADPH oxidase activity in EBV–B cells from patients.
We tested EBV–B cells from the p40phox-deficient patients studied
here, patients with classic CGD, and the first reported patient with
p40phox deficiency (42). In luminol bioluminescence assays, EBV–B
cells from P12, P14, P15, and P20 displayed severely impaired
NADPH oxidase activity (Figure 5C). By contrast, EBV–B cells
from P22 (with c.120_134del) displayed residual luminescence,
consistent with the results obtained following the retrovirusmediated transduction of NCF4 –/– EBV–B cells with the
c.120_134del allele (Figure 2C). This allele is, therefore, also constitutively hypomorphic. We then evaluated the release of H2O2
in EBV–B cells from P12, P14, and P20. H2O2 detection was completely negative, as in cells from classic CGD patients. By contrast,
EBV–B cells from P22 and P15 displayed a residual release of H2O2
(Figure 5C). Finally, EBV–B cells from P12, P14, P15, and P20 were
transduced with a p40phox WT cDNA. The rescue of p40phox protein
expression was confirmed by immunoblotting before functional
assays (Supplemental Figure 6A). Production of O2– in response
to PMA stimulation was restored in the transduced EBV–B cells
(Supplemental Figure 6B). These experiments with EBV–B cells
demonstrate that p40phox is not redundant for NADPH oxidase
complex activity in these cells. They also confirm that 1 of the 8
NCF4 alleles is severely hypomorphic.
Impaired killing of Staphylococcus, but not of fungi, by the
patients’ cells. We then assessed the ability of the patients’ neutrophils to kill various microorganisms that commonly cause disease in patients with classic CGD. We found that the phagocytosis of serum-opsonized E. coli, S. aureus, C. albicans, and SOZ by
the patients’ neutrophils was similar to that by neutrophils from
healthy controls and patients with classic CGD (data not shown).
Nonoxidative phagocyte killing involves the release of the proteolytic content of granules into the phagosome or at the neutrophil
plasma membrane. In the p40phox-deficient neutrophils tested,
protease release from the azurophilic granules (elastase, cathepsin G) in the dye-quenched–BSA (DQ-BSA) assay did not differ
from that of neutrophils from healthy controls (data not shown)
or patients with classic CGD (43). We therefore analyzed the
phagocyte-mediated killing of different species of bacteria and
fungi. The killing of S. aureus by the patients’ neutrophils was markedly impaired for all the patients tested, similar to that observed
for the classic CGD neutrophils (Figure 6A and ref. 44). E. coli killing was unaffected in the patients’ neutrophils, as in those from
patients with classic CGD (Figure 6B and ref. 45). By contrast, the
killing of A. fumigatus was normal or subnormal, whereas neutrophils from patients with classic CGD were completely incapable of
killing these hyphae (Figure 6C). C. albicans killing by the patients’
neutrophils was similar to that by the neutrophils of healthy control
cells when C. albicans was opsonized, whereas neutrophils from
patients with classic CGD were unable to kill this fungus (Figure
6D). Moreover, we observed that inhibition of the germination and
hyphenation of Candida conidia were similar for neutrophils from
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the patients and neutrophils from healthy controls (Supplemental
Figure 7). Finally, we evaluated the formation of neutrophil extracellular traps (NETs), a process for which ROS have been shown to
be essential (46). We assessed NET formation in response to PMA
in 3 patients from kindreds A, B, and C. Only neutrophils from kindred B (expressing p40phox protein) produced NETs. We detected
no NET production in the other p40phox-deficient families tested
(without p40phox protein expression) or for gp91phox-deficient CGD
neutrophils (Supplemental Figure 8). These findings suggest that
NET formation is dependent on p40phox expression. Collectively,
these data indicate that p40phox-deficient neutrophils have normal
fungus-killing capacities, unlike classic CGD neutrophils.
Inflammatory lesions in patients with p40phox deficiency. Deficiency of p40phox is not characterized by the invasive bacterial and
fungal infections seen in patients with classic CGD, but mostly by
inflammatory manifestations as well as autoimmunity and peripheral infections (Tables 1 and 2 and Figure 7A). We identified 20
symptomatic patients, of whom 10 (50%) presented with skin
inflammation (P1, P2, P3, P5, P6, P7, P8, P11, P19, and P24), with
lupus-like cutaneous lesions (P1, P6, and P8) or discoid lupus (P3,
P7, and P11). We found inflammatory, granulomatous GI manifestations in 10 patients (50%), and these included oral ulcers (P1
and P10), abscesses/granulomas (P1, P2, P3, P4, P5, P6, P7, P8, P9,
P10, P11, P23, and P24), periodontitis (P9 and P21), gingivitis or
gum inflammation (P9, P10, P20, P21), esophagitis (P21 and P23),
gastritis (P20), Crohn-like inflammatory bowel disease (IBD) (P1,
P11, P21, P22, P23, and P24), and perianal abscesses/fistula (P11,
P20, P21, and P24). P24 suffered from chronic and severe IBD
requiring immunosuppressive treatment and a total colectomy.
Some lesions were probably both infectious and inflammatory,
as is often seen in CGD. Three patients (15.7%) (P12, P14, and
P19) reportedly suffered from pulmonary infections, including
P12, who was later diagnosed with interstitial lung disease that
responded well to systemic steroids rather than antibiotics, suggesting an autoinflammatory component. Ab evaluations were
performed in some patients (n = 7) suffering from exacerbated
inflammation. P1, P4, P5, P7, P8, and P12 were negative for antinuclear Abs (ANAs). By contrast, P14 was positive for ANAs and
antineutrophil cytoplasmic Abs (ANCAs), suggesting autoimmune
activity in this patient.
Peripheral but not invasive infections in patients with p40phox
deficiency. We investigated the possible infectious causes of
pulmonary manifestations in the cohort. No pathogen was identified in P19. Cutaneous infections were reported in 8 patients
(42%) (P1, P4, P6, P7, P9, P11, P21, and P23), 3 of whom had at
least 1 proven episode of S. aureus infection (P1, P11, and P23).
One patient (P15) had two episodes of disseminated histoplasmosis, which was successfully treated with antifungal drugs and
steroids. Ten patients from six different families were vaccinated
against tuberculosis with live bacillus Calmette-Guérin (BCG)
(Tables 1 and 2). No adverse effects were reported in 9 patients,
whereas P19 developed local lymphadenitis (BCG-itis). This
same patient subsequently suffered from meningitis caused by
Mycobacterium avium. Interestingly, this patient was also heterozygous for a dominant-negative LOF mutation of STAT1, which
is responsible for MSMD (47). Four asymptomatic children,
aged 1, 3, 8, and 10 years at diagnosis of p40phox deficiency, were
jci.org   Volume 128   Number 9   September 2018
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Figure 5. NADPH oxidase activity in p40phox-deficient
mononuclear cells. (A) Extracellular H2O2 production by
MDMs from healthy controls (n = 5), p40phox-deficient
patients (n = 3), and CGD patients (n = 1) upon PMA stimulation (with and without IFN-γ priming). (B) Extracellular
H2O2 production by MDDCs from healthy controls (n = 5),
p40phox-deficient patients (n = 3), and CGD patients (n = 1)
upon PMA stimulation (with and without LPS priming).
(C) Production of O2– (left) and release of H2O2 (right) by
EBV–B cells from healthy controls (n = 2), p40phox-deficient
patients (n = 6), and CGD patients (n = 1) upon PMA stimulation, assessed on the basis of luminol bioluminescence
or Amplex Red test. The results are representative of 2
independent assays. Data represent the mean ± SEM. NS,
no stimulation.

found to have homozygous NCF4 mutations (P13, P16, P17, and
P18), demonstrating incomplete clinical penetrance of the disease, at least until adolescence. In summary, p40phox deficiency
conferred a variable phenotype marked by noninvasive periph3968
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eral infections, mostly of the skin and lungs, and inflammation,
mostly of the GI tract (Tables 1 and 2).
Favorable clinical outcome of p40phox-deficient individuals. Inherited p40phox deficiency differs from classic CGD in terms of cellular
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Figure 6. Pathogen killing activity by neutrophils from p40phox-deficient patients. (A)
S. aureus viability was measured in infected
neutrophils from healthy controls (n = 22),
p40phox-deficient patients (n = 13), and CGD
patients (n = 3). (B) E. coli viability was measured
in infected neutrophils from healthy controls
(n = 20), p40phox-deficient patients (n = 10), and
CGD patients (n = 4). (C) A. fumigatus hypha
viability was measured at different time points
with infected neutrophils from healthy controls
(n = 13), p40phox-deficient patients (n = 13) and
CGD patients (n = 3). (D) C. albicans conidial
viability was measured with infected neutrophils
from healthy controls (n = 15), p40phox-deficient
patients (n = 12), and CGD patients (n = 6). Data
represent the mean ± SEM (n ≥3) or the mean
only (n <3). (A–C) **P < 0.01 and ***P < 0.001,
by 2-tailed Mann-Whitney U test. (D) ***P <
0.001, by 2-tailed Mann-Whitney U test, and P
< 0.0063, by 2-tailed Mann-Whitney U test with
Bonferroni’s correction for multiple comparisons.

phenotype and clinical manifestations, but also in terms of clinical
outcome (Supplemental Table 1). The mean age at symptom onset
was 6 years (range: 1–17 years), later than what was reported for
symptom onset in most patients with classic CGD (Supplemental
Table 2). The mean age at diagnosis (for patients with symptoms)
was 15.3 years (range: 1–46 years), whereas classic CGD is typically
diagnosed before the age of 5 years (Figure 7B and Supplemental
Table 2). All patients included in this study are currently alive and

are between the ages of 1 and 47 years (mean: 15.3 years), whereas a
mortality of close to 4% per year has been reported for classic CGD
(6, 17), with the highest mortality rates during the first 2 decades of
life. The Kaplan-Meier curves for the survival of the largest classic
CGD cohort and this p40phox-deficient cohort differed significantly when comparing XR-CGD and p40phox deficiency (P = 0.0164,
Mantel-Cox analysis) (Figure 7C and Supplemental Table 2).
Fourteen patients were prescribed antibiotic prophylaxis. The
jci.org   Volume 128   Number 9   September 2018
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Figure 7. Clinical manifestation and outcome of p40phox-deficient patients. (A) P20 images show cheilitis, episcleritis, severe chronic cutaneous lesions,
and esophagitis. P21 images show esophagitis. P12 images show multifocal consolidations and infiltrates in both the lungs on x-ray and thorax on CT
scan. P22 images show vulvar lichen planus before (top) and after (bottom) steroid treatment. (B) Distribution of age at diagnosis of CGD in the American
(ref. 7) and European (ref. 9) cohorts and of the p40phox-deficient patients in this study. (C) Kaplan-Meier survival curve compiling survival data on 363 CGD
patients (n = 240 XR CGD and n = 123 AR CGD) from refs. 7 and 19 and on the p40phox-deficient patients studied here.

treatments administered for hyperinflammation included corticosteroids, azathioprine, methotrexate, infliximab, adalimumab,
golimumab, ustekinumab, and hydroxychloroquine. Given the
severity of clinical manifestations, 4 patients underwent allogeneic
HSCT (P11, P14, P20, and P21), resulting in the resolution of symptoms in all these patients. Overall, p40phox deficiency is a severe
condition, but its clinical outcome is nevertheless better than that
of classic CGD.

Discussion

We report the molecular, cellular, and clinical characteristics of
24 patients from 12 families with biallelic mutations of the NCF4
gene, which encodes the NADPH oxidase p40phox protein. Defi3970
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ciency of p40phox is caused by homozygous (23 patients, 11 families) or compound heterozygous (1 patient) mutations in families
from 8 countries. We identified 8 previously undescribed alleles
of the NCF4 gene, 6 of which are completely LOF and caused
complete p40phox deficiency in the corresponding patients. Upon
overexpression, the allele c.120_134del is hypomorphic in EBV–B
cells, and the allele R58C is hypomorphic in NB4 cells. However,
we detected no clinical difference between the patient bearing
these variants and the other patients. We further characterized
phagocytic cells from the p40phox–deficient patients and compared them with those of patients with other molecular causes of
CGD to define more clearly the contribution of human p40phox to
NADPH oxidase activity. Interestingly, NCF4 biallelic mutations
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were found to result in a cellular phenotype related to but clearly
different from that of other forms of CGD. In particular, the
PMA-induced DHR oxidation test widely used for the diagnosis
of CGD gave normal or just below normal values for patients with
inherited p40phox deficiency. Diagnosis of p40phox deficiency can
be achieved using serum-opsonized E. coli as a stimulus in routine
DHR- or Amplex Red–based tests, which must be performed in a
diagnostic laboratory with expertise in analysis of NADPH oxidase
activity. A genetic approach based on Sanger sequencing or NGS
of NCF4 might also facilitate the diagnosis of p40phox deficiency.
The clinical phenotype of patients with p40phox deficiency
is also related to but different from that of patients with classic CGD. The patients in this cohort had peripheral infections
(mostly staphylococcal) and hyperinflammation (mostly granulomatous lesions of the GI tract and skin). Nevertheless, the
frequency of inflammatory lesions is lower than in patients with
classic CGD (48). A few of the patients showed autoimmunity,
but, strikingly, none had the invasive bacterial and fungal infections commonly seen in patients with classic CGD (7–9, 18).
Consistent with these findings, the clinical outcome of p40phox
deficiency is better than that of classic CGD. No deaths were
recorded in this cohort of patients aged 1 to 46 years, whereas
classic CGD–related mortality may reach 35% in its XR and 15%
in its AR forms in the first 3 decades of life (10, 17). Moreover,
4 patients remained asymptomatic at 1 to 10 years of age, and
the age at clinical onset ranged from 1 to 17 years in patients with
symptoms. The incomplete clinical penetrance observed at 1 to
10 years of age also contrasts strongly with observations for classic CGD (7–9, 18). Thus, the healthy siblings of probands should
be tested immunologically and genetically. Curative and preventive treatments for CGD are based on prolonged treatment
with regimens of antibiotics, antifungal drugs, exogenous IFN-γ,
and, increasingly, allogeneic HSCT. Decisions concerning allogeneic HSCT for patients with p40phox deficiency should be made
on a case-by-case basis, given the milder overall phenotype and
greater variability between patients. Likewise, the immediate
initiation of antifungal prophylaxis may not be required, whereas
treatment with immunosuppressive agents may be indicated.
One patient with disseminated histoplasmosis (P15) was
included in this cohort. However, to our knowledge, no patient
with CGD has ever been reported to suffer from this fungal disease. This situation is reminiscent of that of tuberculosis, which
is actually much more common than initially thought in CGD
patients living in areas of endemic disease (49). Its pathogenesis has been attributed to defects of NADPH oxidase activity
in mononuclear phagocytes (25). The normal NADPH oxidase
activity of the p40phox-deficient mononuclear phagocytes tested
suggests that histoplasmosis may actually be due to the disruption of NADPH oxidase activity in tissue-resident macrophages
and DCs, which were not tested in patients with classic CGD or
p40phox deficiency (50). Another patient in this cohort (P19) had
BCG and M. avium diseases. BCG disease has been reported
in CGD patients, but cases of M. avium complex infection have
rarely been reported in this population. Moreover, these 2 mycobacterial infections are probably not related to p40phox deficiency in P19, because this patient also carries a dominant-negative STAT1 mutation responsible for MSMD (47). Finally, 1 of
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the patients in our cohort (P20) had adenocarcinoma, possibly
related to chronic Crohn’s colitis, although other factors may
also be involved.
Other clinical features of the patients can be understood in
light of their cellular phenotypes. In vitro S. aureus killing by neutrophils from patients with p40phox deficiency or classic CGD was
severely impaired, whereas E. coli killing by neutrophils from these
patients was similar to that by neutrophils from healthy controls. S.
aureus killing is a ROS-dependent process, whereas E. coli killing
is relatively ROS independent (45, 51). The absence of invasive S.
aureus infections in the p40phox-deficient patients was unexpected
and remains unexplained, as both in vitro S. aureus–induced oxidase activity and S. aureus killing are as severely impaired in these
patients as in those with classic CGD, who do suffer from invasive
S. aureus infections. The almost normal killing of fungi by neutrophils from p40phox-deficient patients, even though the killing
of Candida and Aspergillus is ROS dependent (52, 53), is of direct
clinical relevance and contrasts with the situation in patients with
classic CGD (54). The lack of invasive fungal infections is highly
consistent with our in vitro biochemical findings for phagocytic
cells from p40phox-deficient patients. Residual NADPH oxidase
activity was generally higher in p40phox-deficient cells than in
classic CGD cells, and in vitro fungal killing was largely unaffected. This situation contrasts with that for classic CGD, in which
invasive fungal infections are among the most feared and lifethreatening complications, despite antimicrobial prophylaxis (10),
and for which fungus killing is impaired in vitro. Given the importance of p40phox-PX interactions with PI(3)P in the phagosome for
the NADPH oxidase activity elicited by bacteria, the lack of effect
on C. albicans–induced ROS production and killing is surprising.
Normal fungal killing in these patients may also result from the
residual fungus-induced NADPH oxidase activity observed, suggesting a p40phox-independent mechanism for ROS production
that is preferentially triggered by fungi. This implies that ROS production would have to exceed a certain threshold for effective fungal killing. Further studies of late phagosome formation in relation
to p40phox localization and ROS formation might clarify the differences in S. aureus and C. albicans killing, which diverge in patients
with p40phox deficiency, but not in those with classic CGD.
Interestingly, our studies of monocytes, MDMs, and MDDCs
suggest that these cell types are not dependent on p40phox for
PMA-induced NADPH oxidase activity. This situation contrasts
with that for MSMD-causing gp91phox mutations, which disrupt
NADPH oxidase activity in MDMs but not in other phagocytes
(neutrophils, monocytes, and MDDCs) (25, 41). The conservation of NADPH oxidase activity may explain the milder infectious
phenotype of p40phox-deficient patients than of patients with classic CGD, including the absence of invasive bacterial and fungal
infections. This feature may be specific to human cells, as p40phoxmutant mouse macrophages (either KO or R58A mice) have
impaired NADPH oxidase activity upon stimulation with a physiological stimulus (36). The PX domain of p40phox is thought to
have a high affinity for and specificity of binding to PI(3)P, a lipid
on phagosomal membranes, leading to enhanced NADPH oxidase activity. Further studies are required to evaluate NADPH
oxidase activity in phagocytic cells other than neutrophils in
patients with p40phox deficiency or classic CGD. In this respect,
jci.org   Volume 128   Number 9   September 2018
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approaches involving the derivation of different types of phagocytes from induced pluripotent stem cells may be particularly
effective (55).
Excessive granulomatous inflammation of the skin and GI
tract was the most common clinical phenotype observed in this
cohort of patients. Systemic lupus–like symptoms are rare in
patients with CGD (7, 12, 20) and in the p40phox-deficient patients
reported here. Enhanced inflammation has also been reported in
mice with p40phox deficiency (36, 37, 56). Mouse p40phox has been
reported to be required for the expression of glycan structure–
modifying enzymes, which may underlie the recruitment of neutrophils to resolve intestinal inflammation and facilitate wound
healing (37). Mouse macrophages with p40phox p.R58A/R58A or
KO mutations also produce smaller than normal amounts of ROS
(36). The excessive inflammation seen in classic CGD and p40phox
deficiency indicates that ROS play a role in immune regulation
(12, 57). Patients with p40phox deficiency display at least as much
inflammation as those with classic CGD, but have higher levels
of ROS production. The ROS produced by neutrophils may contribute to the clearance of apoptotic cells or cell debris, and their
deficiency may contribute to inflammation in various ways,
including aberrant efferocytosis, for example (58–62). Alternatively, the inflammation observed in classic CGD and p40phox
deficiency may be due to abnormal ROS production by circulating
B cells. This possibility was already suggested in the first report
describing a p40phox-deficient patient (42). Our results also suggest
that NADPH activity is defective in all p40phox-deficient EBV–B
cells tested, confirming that p40phox is not redundant in human B
cells. An understanding of the excessive inflammation in patients
with classic CGD or p40phox deficiency will require further studies of the respiratory burst in various other cell types, including
tissue-resident DCs and macrophages, and in different types of
circulating B cells.

Methods

Cell lines. NB4 cells were obtained from DSMZ (catalog ACC 207).
HEK293T cells were obtained from the American Tissue Culture Collection (ATCC) (catalog CRL-3216).
Ion torrent sequencing, WES, copy number variation, and Sanger sequencing. We extracted genomic DNA from blood samples with the iPrep PureLink gDNA Blood Kit and iPrep Instruments (Life Technologies, Thermo
Fisher Scientific). An AmpliSeq Custom Panel (Thermo Fisher Scientific)
was used in families A–E, J, and K. A targeted NGS panel for PID was used
in kindred I (63) and another for IBD was used in kindred J (64).
WES was performed with 3 μg DNA from kindreds F, G, H, and L.
Exome capture was performed with the SureSelect Human All Exon
72 Mb Kit (Agilent Technologies). SNP arrays for CNV or ancestral
founder effect were used with the Genome-Wide Human SNP Array
6.0 (Affymetrix) in kindreds A, C, E, G, J, K, and L.
For confirmation of the mutations detected and the analysis of
familial segregation for kindred members, we amplified the flanking
regions of the variants obtained, including part of the intronic regions
for all NCF4 exons studied. Primers and conditions are described in
detail in Supplemental Table 3.
NADPH oxidase functional assays. NADPH oxidase activity on neutrophils and NB4 cells was assessed by measuring extracellular H2O2
release with an Amplex Red Kit (Life Technologies, Thermo Fisher
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Scientific). Cells were stimulated with PMA (100 ng/ml), PAF (1 μM)
followed by fMLF (1 μM) (all from Sigma-Aldrich), E. coli (OD600 0.1,
strain ML-35 in the presence of 2 mM azide), and S. aureus (OD600 0.1,
strain Oxford in the presence of 2 mM azide) or A. fumigatus hyphae
(clinical isolate). We used 0.25 × 106 cells/ml, and the experiments
were performed as previously described (65). The same method was
used for the MDMs, MDDCs, and EBV–B cells, except that 400 ng/ml
PMA was also added to the cells. The above-mentioned reagents and
E. coli, S. aureus, and A. fumigatus strains were used in all experiments.
Particles were opsonized with 10% (v/v) pooled human serum. MDMs
and MDDCs were obtained by differentiation as previously described
(25, 41). MDMs were cultured for 16 to 18 hours with 1 mg/ml purified protein derivatives (PPDs) (tuberculin PPD Batch RT49, Statens
Serum Institute) or 5 × 103 IFN-γ IU/ml (Imukin, Boehringer Ingelheim) and then washed and activated by incubation for 30 minutes
with PMA, or left unactivated. MDDCs were treated with LPS (1 μg/
ml Salmonella minnesota, Sigma-Aldrich), alone or immediately before
treatment with PMA.
The production of intracellular ROS by neutrophils, monocytes,
and NB4 cells was analyzed with DHR (Thermo Fisher Scientific), as previously described (66). We added 0.5 μM DHR in DMSO
to 2.5 × 106 neutrophils. PMA (100 ng/ml), serum-opsonized E. coli
or S. aureus (OD600 0.1 in the presence of 2 mM azide), C. albicans
(OD625 0.1, strain SC5314), or SOZ (0.1 mg/ml) was then added. At
the desired time points, samples were added to STOP buffer (0.5%
[w/v] PFA, 1% [w/v] BSA, and 20 mM NaF in PBS), and the amount
of rhodamine-1,2,3 (mean MFI [mean fluorescence intensity]) was
assessed by flow cytometry using a FACSCanto II/LSR (BD Biosciences) and expressed as the percentage of rhodamine-1,2,3 produced by
healthy control cells.
ROS production by monocytes was analyzed by assessing DHR
after stimulation with PMA (400 ng/ml) in kindreds E, F, G, H, and J,
using a Galios FACS Analyzer (Beckman Coulter) and an LSR Fortessa
Cell Analyzer (BD). DHR is expressed as a percentage of the control,
and MFI values were normalized against the healthy control.
Generation of NB4 p40phox-KO cells. The Optimized CRISP Design
Tool (http://crispr.mit.edu/) was used (Zhang laboratory) to determine the Cas9 target sites present in the coding sequence of p40phox.
An oligomer was cloned into the BsmBI site of pLentiCRISPR v2. The
constructs were grown in E. coli Stbl3. Lentiviral particles were generated by the transient cotransfection of HEK293T cells with pLentiCRISPRv2, p40phox-KO, psPAX2, and pCMV-VSVg using TransIT-LT1
Transfection Reagent (Mirusbio). The day after transfection, the cells
were plated on NB4 medium. The virus-containing supernatant was
harvested on days 2 and 3 after transfection and filtered through 0.45μm pores, and 1 ml was used with 5 × 105 NB4 cells on 2 successive
days. Transduced NB4 cells were selected with 1 μg/ml puromycin
(InvivoGen). Surviving cells were plated on limiting dilution medium
in a 96-well plate at a density of 0.5 cells/150 μl, and growing clones
were routinely maintained. The p40phox levels of these clones were
assessed by Western blotting. A clone with no p40phox expression
was obtained when the 5′-GTCAGCAATGTTGGCCGAGA-3′ target
sequence was used.
Statistics. Statistical analysis was performed with GraphPad
Prism, version 7.02 (GraphPad Software). All data sets were considered
non-normally distributed, as the numbers were too low for normality
tests. A 2-tailed Mann Whitney U test was used for statistical analy-
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sis of 2-group comparisons: e.g., controls vs. kindred A, controls vs.
kindred B, etc. A P value of less than 0.05 was considered statistically
significant. For data sets containing multiple independent variables,
the Bonferroni correction for multiple testing was applied, adjusting
the P value depending on the number of variables. When the sample
number was 3 or more, error bars were added to the graph. Where no
error bars are visible, the SEM was smaller than the symbol (for n ≥3).
Study approval. The study was approved by the IRBs of the INSERM,
The Rockefeller University, and Necker Hospital for Sick Children; the
Medical Ethics Committee of the Academic Medical Center/Emma
Children’s Hospital; and by the bioethics committee for research in
humans (CBE-SIU) of the UdeA. All procedures were conducted in
accordance with the 1975 Declaration of Helsinki, as revised in 2013.

Author contributions

TWK and JB are the principal investigators and conceived the
study. AVDG, ANP, DBK, ATJT, PJHV, AAA, LP, MVH, MG, COQ,
CAAF, MEA, NW, CD, EN, RPG, JLVH, and KM performed the
experiments. DR, DBK, JIG, JLC, MCD, and TKVDB contributed
to the design of the study. ARB, SOB, JV, SM Holland, ET, BB, MO,
MMV, SV, IM, JLF, JSL, AC, FCH, PI, AMM, NCB, PDA, AW, CB,
DF, CHH, HW, SM Hughes, and HLM contributed to the collection of samples from the patients and provided a clinical overview.
CG, MDB, KVL, JFA, FC, VR, VB, MB, and LA were responsible for
genetic analysis. All authors revised the manuscript and approved
the final manuscript. AVDG, ANP, DR, JLC, JB, and TWK analyzed the results and wrote the manuscript.

Acknowledgments

The authors thank all the patients and their relatives as well as
the treatment teams for their participation in this study. We also
thank Céline Desvallées, Dominick Papandrea, Cécile Patissier,
and Yelena Nemirovskaya at the HGMI laboratory (Rockefeller
University branch) and the Institute Imagine branch for administrative assistance. We thank all the members of the Blood Cell
Research Department and the HGMI Laboratory for helpful discussions. We acknowledge the use of the biological resources
of the Imagine Institute DNA-Biobank (BB-33-00065). AVDG
was supported by the Sanquin Blood Supply Product and Pro1. Roos D, Tool ATJ, van Leeuwen K, de Boer M.
Biochemical and genetic diagnosis of chronic
granulomatous disease. In: Seger RA, Roos D,
Segal BH, Kuijpers TW, eds. Chronic Granulomatous Disease. Geneticcs, Biology And Clinical
Management. New York, New York, USA: Nova
Biomedical Press; 2017:231–300.
2. Janeway CA, Craig J, Davidson M, Downey W,
Gitlin D, Sullivan JC. Hypergammaglobulinemia associated with severe, recurrent and
chronic non-specific infection. Am J Dis Child.
1954;88:388–392.
3. Holmes B, Quie PG, Windhorst DB, Good RA.
Fatal granulomatous disease of childhood. An
inborn abnormality of phagocytic function.
Lancet. 1966;1(7449):1225–1228.
4. Royer-Pokora B, et al. Cloning the gene for an
inherited human disorder — chronic granulomatous disease — on the basis of its chromosomal

cess Development Cellular Products Fund (PPOC 1957). ANP
was supported by the CONACYT National PhD Fellowship Program. The HGMI Laboratory was funded in part by the NIAID
(5R01AI089970 and 5R37AI095983), the National Center for
Research Resources, and the National Center for Advancing Sciences of the NIH (8UL1TR000043), The Rockefeller University,
the St. Giles Foundation, INSERM, Paris Descartes University,
the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), and the French
National Research Agency (ANR) under the “Investments for the
Future” program (ANR-10IAHU-01, to the Imagine Institute),
ANR-IFNPHOX/ANR-13-ISV3-0001-01, and ANR-GENMSMD/ANR-16-CE17-0005-01 (to JB), ECOSNord-C14S01 (to JB
and JLF), and COLCIENCIAS (576-2013:111556934990, to JLF).
KM was supported by a Japan Foundation for Pediatric Research
fellowship grant. AMM was funded by the Canadian Institutes of
Health Research (CIHR) and The Leona M. and Harry B. Helmsley Charitable Trust. This work was supported in part by the
Division of Intramural Research, NIAID, NIH and was funded in
part with federal funds from the National Cancer Institute, NIH
(HHSN261200800001E). The content of this publication does
not necessarily reflect the views or policies of the Department of
Health and Human Services, nor does mention of trade names,
commercial products, or organizations imply endorsement by
the US Government.
Address correspondence to: Dirk Roos, Sanquin Research, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands. Phone:
00.31.20.5123317; Email: d.roos@sanquin.nl. Or to: Jean-Laurent
Casanova, The Rockefeller University, 1230 York Avenue, New
York, New York 10065, USA. Phone: 212.327.7331; Email jean-laurent.casanova@rockefeller.edu. Or to: Taco W. Kuijpers, Sanquin
Research, P.O. Box 9190, 1006 AD Amsterdam, The Netherlands.
Phone: 00.31.20.5123224; Email t.w.kuijpers@amc.uva.nl. Or to:
Jacinta Bustamante, Paris Descartes University, Imagine Institute,
Necker Hospital for Sick Children, INSERM U-1163, Laboratory of
Human Genetics of Infectious Diseases, 24 Boulevard du Montparnasse, 75015 Paris, France. Phone: 33.1.42.75.43.20; Email
jacinta.bustamante@inserm.fr.

location. Nature. 1986;322(6074):32–38.
5. Dinauer MC, Orkin SH, Brown R, Jesaitis AJ,
Parkos CA. The glycoprotein encoded by the
X-linked chronic granulomatous disease locus
is a component of the neutrophil cytochrome b
complex. Nature. 1987;327(6124):717–720.
6. Segal AW, et al. Absence of cytochrome b-245 in
chronic granulomatous disease. A multicenter
European evaluation of its incidence and relevance. N Engl J Med. 1983;308(5):245–251.
7. Winkelstein JA, et al. Chronic granulomatous
disease. Report on a national registry of 368
patients. Medicine (Baltimore). 2000;79(3):155–169.
8. de Oliveira-Junior EB, et al. Clinical and Genotypic Spectrum of Chronic Granulomatous Disease in 71 Latin American Patients: First Report
from the LASID Registry. Pediatr Blood Cancer.
2015;62(12):2101–2107.
9. van den Berg JM, et al. Chronic granulomatous

disease: the European experience. PLoS One.
2009;4(4):e5234.
10. Marciano BE, et al. Common severe infections in
chronic granulomatous disease. Clin Infect Dis.
2015;60(8):1176–1183.
11. Parvaneh N, et al. Visceral leishmaniasis in two
patients with IL-12p40 and IL-12Rβ1 deficiencies. Pediatr Blood Cancer. 2017;64(6):e26362.
12. Magnani A, et al. Inflammatory manifestations
in a single-center cohort of patients with chronic
granulomatous disease. J Allergy Clin Immunol.
2014;134(3):655–662.e8.
13. Marciano BE, Segal BH, Holland SM. Inflammatory manifestations in chronic granulomatous
disease. In: Seger RA, Roos D, Segal H, Kuijpers
TW, eds. Chronic Granulomatous Disease. Geneticcs,
Biology And Clinical Management. New York, New
York, USA: Nova Biomedical Press; 2017:163–201.
14. Huang C, et al. Genetic Risk for Inflammatory

jci.org   Volume 128   Number 9   September 2018

3973

RESEARCH ARTICLE
Bowel Disease Is a Determinant of Crohn’s Disease Development in Chronic Granulomatous Disease. Inflamm Bowel Dis. 2016;22(12):2794–2801.
15. van de Veerdonk FL, Dinauer MC. Dysfunctional
processes regulating IL-1B in chronic granulomatous disease. In: Seger RA, Roos D, Segal H, Kuijpers TW, eds. Chronic Granulomatous Disease.
Geneticcs, Biology And Clinical Management. New
York, New York, USA: Nova Biomedical Press;
2017:69–87.
16. Ben Abdallah Chabchoub R, Turki H, Mahfoudh A. [Systemic lupus erythematosus in a
boy with chronic granulomatous disease: case
report and review of the literature]. Arch Pediatr.
2014;21(12):1364–1366.
17. Kuhns DB, et al. Residual NADPH oxidase and
survival in chronic granulomatous disease.
N Engl J Med. 2010;363(27):2600–2610.
18. Wolach B, et al. Chronic granulomatous disease:
Clinical, functional, molecular, and genetic
studies. The Israeli experience with 84 patients.
Am J Hematol. 2017;92(1):28–36.
19. Köker MY, et al. Clinical, functional, and genetic
characterization of chronic granulomatous
disease in 89 Turkish patients. J Allergy Clin
Immunol. 2013;132(5):1156–1163.e5.
20. Kang EM, Marciano BE, DeRavin S, Zarember
KA, Holland SM, Malech HL. Chronic granulomatous disease: overview and hematopoietic
stem cell transplantation. J Allergy Clin Immunol.
2011;127(6):1319–26;quiz1327.
21. Segal BH, Leto TL, Gallin JI, Malech HL, Holland
SM. Genetic, biochemical, and clinical features
of chronic granulomatous disease. Medicine
(Baltimore). 2000;79(3):170–200.
22. Roos D. Chronic granulomatous disease. Br Med
Bull. 2016;118(1):50–63.
23. Roos D, de Boer M. Molecular diagnosis of
chronic granulomatous disease. Clin Exp Immunol. 2014;175(2):139–149.
24. Roos D, et al. Two CGD families with a
hypomorphic mutation in the activation
domain of p67phox. J Clin Cell Immunol.
2014;5(3):1000231.
25. Bustamante J, et al. Germline CYBB mutations
that selectively affect macrophages in kindreds
with X-linked predisposition to tuberculous
mycobacterial disease. Nat Immunol.
2011;12(3):213–221.
26. Matute JD, et al. A new genetic subgroup of
chronic granulomatous disease with autosomal
recessive mutations in p40 phox and selective
defects in neutrophil NADPH oxidase activity.
Blood. 2009;114(15):3309–3315.
27. Zhan S, et al. Genomic structure, chromosomal
localization, start of transcription, and tissue
expression of the human p40-phox, a new
component of the nicotinamide adenine dinucleotide phosphate-oxidase complex. Blood.
1996;88(7):2714–2721.
28. Matute JD, Arias AA, Dinauer MC, Patiño PJ.
p40phox: the last NADPH oxidase subunit. Blood
Cells Mol Dis. 2005;35(2):291–302.
29. Nunes P, Demaurex N, Dinauer MC. Regulation
of the NADPH oxidase and associated ion fluxes
during phagocytosis. Traffic. 2013;14(11):1118–1131.
30. Odell EW, Segal AW. Killing of pathogens associated with chronic granulomatous disease

3974

The Journal of Clinical Investigation  
by the non-oxidative microbicidal mechanisms of human neutrophils. J Med Microbiol.
1991;34(3):129–135.
31. Ellson CD, Davidson K, Ferguson GJ, O’Connor
R, Stephens LR, Hawkins PT. Neutrophils from
p40phox–/– mice exhibit severe defects in NADPH
oxidase regulation and oxidant-dependent bacterial killing. J Exp Med. 2006;203(8):1927–1937.
32. Bagaitkar J, Matute JD, Austin A, Arias AA,
Dinauer MC. Activation of neutrophil respiratory burst by fungal particles requires
phosphatidylinositol 3-phosphate binding to
p40phox in humans but not in mice. Blood.
2012;120(16):3385–3387.
33. Deffert C, et al. Hyperinflammation of chronic
granulomatous disease is abolished by NOX2
reconstitution in macrophages and dendritic
cells. J Pathol. 2012;228(3):341–350.
34. Rodrigues-Sousa T, et al. Deficient production of
reactive oxygen species leads to severe chronic
DSS-induced colitis in Ncf1/p47phox-mutant
mice. PLoS One. 2014;9(5):e97532.
35. Bao S, Carr ED, Xu YH, Hunt NH. Gp91(phox)
contributes to the development of experimental
inflammatory bowel disease. Immunol Cell Biol.
2011;89(8):853–860.
36. Bagaitkar J, et al. PI(3)P-p40phox binding regulates NADPH oxidase activation in mouse macrophages and magnitude of inflammatory responses in vivo. J Leukoc Biol. 2017;101(2):449–457.
37. Conway KL, et al. p40phox expression regulates
neutrophil recruitment and function during the
resolution phase of intestinal inflammation.
J Immunol. 2012;189(7):3631–3640.
38. Prando C, et al. Paternal uniparental isodisomy
of chromosome 6 causing a complex syndrome
including complete IFN-gamma receptor 1 deficiency. Am J Med Genet A. 2010;152A(3):622–629.
39. Genin E, Tullio-Pelet A, Begeot F, Lyonnet S, Abel
L. Estimating the age of rare disease mutations:
the example of Triple-A syndrome. J Med Genet.
2004;41(6):445–449.
40. Dusi S, et al. Nicotinamide-adenine dinucleotide
phosphate oxidase assembly and activation in
EBV-transformed B lymphoblastoid cell lines
of normal and chronic granulomatous disease
patients. J Immunol. 1998;161(9):4968–4974.
41. Conti F, et al. Phagocyte nicotinamide adenine
dinucleotide phosphate oxidase activity in patients
with inherited IFN-γR1 or IFN-γR2 deficiency.
J Allergy Clin Immunol. 2015;135(5):1393–1395.e1.
42. Crotzer VL, et al. Cutting edge: NADPH oxidase
modulates MHC class II antigen presentation by
B cells. J Immunol. 2012;189(8):3800–3804.
43. Voetman AA, Weening RS, Hamers MN, Meerhof
LJ, Bot AA, Roos D. Phagocytosing human neutrophils inactivate their own granular enzymes.
J Clin Invest. 1981;67(5):1541–1549.
44. Repine JE, Clawson CC. Quantitative measurement of the bactericidal capability of neutrophils
from patients and carriers of chronic granulomatous disease. J Lab Clin Med. 1977;90(3):522–528.
45. Rosen H, Michel BR. Redundant contribution
of myeloperoxidase-dependent systems to
neutrophil-mediated killing of Escherichia
coli. Infect Immun. 1997;65(10):4173–4178.
46. Fuchs TA, et al. Novel cell death program leads
to neutrophil extracellular traps. J Cell Biol.

jci.org   Volume 128   Number 9   September 2018

2007;176(2):231–241.
47. Kagawa R, et al. Alanine-scanning mutagenesis of
human signal transducer and activator of transcription 1 to estimate loss- or gain-of-function variants.
J Allergy Clin Immunol. 2017;140(1):232–241.
48. Khangura SK, et al. Gastrointestinal features
of chronic granulomatous disease found
during endoscopy. Clin Gastroenterol Hepatol.
2016;14(3):395–402.e5.
49. Conti F, et al. Mycobacterial disease in patients
with chronic granulomatous disease: a retrospective analysis of 71 cases. J Allergy Clin Immunol.
2016;138(1):241–248.e3.
50. Subramanian Vignesh K, Landero Figueroa JA,
Porollo A, Caruso JA, Deepe GS. Granulocyte
macrophage-colony stimulating factor induced
Zn sequestration enhances macrophage superoxide and limits intracellular pathogen survival.
Immunity. 2013;39(4):697–710.
51. Zhao XW, et al. Defects in neutrophil granule
mobilization and bactericidal activity in familial
hemophagocytic lymphohistiocytosis type 5
(FHL-5) syndrome caused by STXBP2/Munc18-2
mutations. Blood. 2013;122(1):109–111.
52. Gazendam RP, et al. Human neutrophils use
different mechanisms to kill Aspergillus fumigatus
Conidia and Hyphae: evidence from phagocyte
defects. J Immunol. 2016;196(3):1272–1283.
53. Boyle KB, Stephens LR, Hawkins PT. Activation
of the neutrophil NADPH oxidase by Aspergillus
fumigatus. Ann N Y Acad Sci. 2012;1273:68–73.
54. Lehrer RI, Cline MJ. Interaction of Candida
albicans with human leukocytes and serum.
J Bacteriol. 1969;98(3):996–1004.
55. Hetzel M, et al. Hematopoietic stem cell
gene therapy for IFNγR1 deficiency protects
mice from mycobacterial infections. Blood.
2018;131(5):533–545.
56. Winter S, Hultqvist Hopkins M, Laulund F, Holmdahl R. A reduction in intracellular reactive oxygen species due to a mutation in NCF4 promotes
autoimmune arthritis in mice. Antioxid Redox
Signal. 2016;25(18):983–996.
57. De Ravin SS, et al. Chronic granulomatous disease as a risk factor for autoimmune disease.
J Allergy Clin Immunol. 2008;122(6):1097–1103.
58. Fernandez-Boyanapalli RF, et al. Impaired
apoptotic cell clearance in CGD due to altered
macrophage programming is reversed by phosphatidylserine-dependent production of IL-4.
Blood. 2009;113(9):2047–2055.
59. Greenlee-Wacker MC, Rigby KM, Kobayashi
SD, Porter AR, DeLeo FR, Nauseef WM. Phagocytosis of Staphylococcus aureus by human
neutrophils prevents macrophage efferocytosis
and induces programmed necrosis. J Immunol.
2014;192(10):4709–4717.
60. Greenlee-Wacker MC, Nauseef WM. IFN-γ
targets macrophage-mediated immune responses
toward Staphylococcus aureus. J Leukoc Biol.
2017;101(3):751–758.
61. Fernandez-Boyanapalli R, et al. Impaired phagocytosis of apoptotic cells by macrophages in
chronic granulomatous disease is reversed by
IFN-γ in a nitric oxide-dependent manner.
J Immunol. 2010;185(7):4030–4041.
62. Marks DJ, Miyagi K, Rahman FZ, Novelli M,
Bloom SL, Segal AW. Inflammatory bowel dis-

RESEARCH ARTICLE

The Journal of Clinical Investigation  
ease in CGD reproduces the clinicopathological
features of Crohn’s disease. Am J Gastroenterol.
2009;104(1):117–124.
63. Frans G, et al. PID in disguise: molecular
diagnosis of IRAK-4 deficiency in an adult
previously misdiagnosed with autosomal
dominant hyper IgE syndrome. J Clin Immunol.
2015;35(8):739–744.

64. Charbit-Henrion F, et al. Diagnostic yield of
next-generation sequencing in very early-onset
inflammatory bowel diseases: a multicenter study
[published online ahead of print May 18, 2018].
J Crohns Colitis. https://doi.org/10.1093/
ecco-jcc/jjy068.
65. Kuijpers TW, Alders M, Tool AT, Mellink C, Roos
D, Hennekam RC. Hematologic abnormalities

in Shwachman Diamond syndrome: lack of
genotype-phenotype relationship. Blood.
2005;106(1):356–361.
66. van Pelt LJ, van Zwieten R, Weening RS, Roos D,
Verhoeven AJ, Bolscher BG. Limitations on the
use of dihydrorhodamine 123 for flow cytometric
analysis of the neutrophil respiratory burst.
J Immunol Methods. 1996;191(2):187–196.

jci.org   Volume 128   Number 9   September 2018

3975

